BMS lowers IPO target to $600M

In what analysts see as a test of the paltry IPO market, Bristol-Myers Squibb will sell off part of its Mead Johnson subsidiary for $21 to $24 per share, hoping to bring in $600 million. That's a lot less than it originally expected to raise from Mead Johnson: $1 billion. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.